Data synthesis and analysis The comparison of outcomes among the different glucose-lowering drug classes was made using a frequentist approach for direct and indirect treatment comparisons for each endpoint [19]
Hims & Hers Weight Loss: Who is Eligible
The STEP-1 trial showed that once-weekly semaglutide led to a net 15% weight loss in non-diabetic, obese/overweight patients
What to Expect Week by Week Understanding what happens during each phase of treatment helps set realistic expectations and reduces anxiety about the process
GLP-1s Mechanism in Appetite & Weight Regulation Glucagon-like peptide 1 (GLP-1) is a cleavage product of the pre-proglucagon gene which is expressed in the -cells of the pancreas, the L-cells of the intestine, and neurons located in the caudal brainstem and hypothalamus
Side Effects: There were no serious incidents of hypoglycaemia (too little blood sugar) reported, nor were there any maglinancies in the thyroid gland or reports persistent hyperglycaemia (too much blood sugar) 8% of patients across all Retatrutide groups collectively did not continue treatment because of an adverse event The most commonly reported adverse events in people taking Retatrutide were gastrointestinal in nature (constipation, diarrhea, vomiting, nasuea), were mild to moderate in severity, and happened more often in people taking larger doses of Retatrutide All in all, patients on Retatrutide experienced a dramatic improvement in insulin sensitivity and any observed side effects were not significantly different in severity, type or frequency compared to the Phase 2 trial for obesity
